Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Multicenter phase 2 study of subcutaneous isatuximab plus bortezomib , lenalidomide and dexamethasone (Isa Sc-VRd) in transplant ineligible newly diagnosed multiple myeloma: Final analysis of the isasocut study (IFM 2022-05)

View Full Paper
Ask AI
Bookmark
Share

Authors

RZRick ZhangTBThorsten BraunRTReza Tabrizi

Discussion

Loading...

Member takes

Overview

Phase 2 study shows high VGPR in transplant-ineligible multiple myeloma, suggesting a new standard of care.

Key Points

  • The ≥VGPR rate was 87.8%, with 35.1% achieving MRD negativity, indicating strong treatment effectiveness.
  • Analysis included 74 patients across 23 centers, demonstrating significant results in a diverse population.
  • Prospective, multicenter, open-label study evaluated treatment efficacy and safety in older adults with NDMM.
  • Findings support the use of Isatuximab as a less intensive alternative to IV regimens in multiple myeloma management.

Cite This Study

Zhang et al. (2025) studied this question.

synapsesocial.com/papers/69362f694fa91c937236df4chttps://doi.org/10.1182/blood-2025-2275
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Isatuximab with bortezomib, cyclophosphamide, and dexamethasone followed by isatuximab and lenalidomide maintenance in newly diagnosed multiple myeloma patients with severe renal impairment: Final analysis of a phase 2 study by the greek myeloma study group2025
  2. 2Isatuximab (Isa) plus lenalidomide (R), Bortezomib (V), and dexamethasone (d) (Isa-RVd) as induction therapy in transplant-eligible patients (pts) with newly diagnosed multiple myeloma (NDMM): Primary analysis of parallel phase 2 studies by the Dana-Farber Cancer Institute (DFCI) and Cancer Trials Ireland (CTI)2025
  3. 3Isatuximab (Isa) subcutaneous (SC) via an on-body injector (OBI) vs isa intravenous (IV), plus pomalidomide and dexamethasone (Pd) in relapsed/refractory multiple myeloma (RRMM): East asia subgroup results from the randomized, non-inferiority, phase 3 iraklia study2025
  4. 4Isatuximab subcutaneous in relapsed/refractory multiple myeloma: Exposure-response and serum m-protein dynamics analyses from phase 3 iraklia Study and the phase 1b Study2025 · 1 citations
  5. 5Efficacy and safety of isa-vrd in elderly patients with or without frailty criteria: Pooled analysis of imroz and phase 1b studies in newly diagnosed multiple myeloma patients2025 · 1 citations